Mounjaro differs from some other weight loss medications because tirzepatide acts on both GLP-1 and GIP hormone pathways rather than GLP-1 activity alone
The approval came after clinical trials involving 3,477 patients (2,519 on Zepbound and 958 on a placebo): Patients taking 5mg of Zepbound lost 15% of their body weight (study 1) Patients taking 10mg of Zepbound lost 19.5% (study 1) and 12.8% (study 2) of their body weight Patients taking 15mg of Zepbound lost 20.9% (study 1) and 14.7% (study 2) of their body weight Patients taking the placebo lost 3.1% (study 1) and 3.2% (study 2) of their body weight Zepbound was released to market on December 5, 2023, with six available dosages available to those with a prescription: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, and 15mg
Trocchio LL et al
For optimal skin wellness benefits, consistent daily use over 48 weeks is recommended
By combining GLP-1 with a structured strength training regimen, we aim to maximize muscle recovery, enhance energy levels, and improve overall workout efficiency
To investigate the genetic basis of this variability, here we conduct a genome-wide association study of self-reported weight loss and treatment-related side effects in 27,885 people following GLP1 receptor agonist therapy